Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia

被引：2

作者：

Morgensztern, D ^{[1
]}

Rosado, MF ^{[1
]}

Raez, LE ^{[1
]}

Santos, ES ^{[1
]}

Cassileth, PA ^{[1
]}

机构：

[1] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33152 USA

来源：

LEUKEMIA & LYMPHOMA | 2005年 / 46卷 / 02期

关键词：

D O I：

10.1080/10428190400015667

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：297 / 298

页数：2

共 10 条

[1] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].

Druker, BJ ;

Sawyers, CL ;

Kantarjian, H ;

Resta, DJ ;

Reese, SF ;

Ford, JM ;

Capdeville, R ;

Talpaz, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042

[2] Results of a prospective phase 2 study combining imatinib, mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase [J].

Gardembas, M ;

Rousselot, P ;

Tulliez, M ;

Vigier, M ;

Buzyn, A ;

Rigal-Huguet, F ;

Legros, L ;

Michallet, M ;

Berthou, C ;

Cheron, N ;

Maloisel, F ;

Mahon, FX ;

Facon, T ;

Berthaud, P ;

Guilhot, J ;

Guilhot, F .

BLOOD, 2003, 102 (13) :4298-4305

[3] Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia:: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis [J].

Gleissner, B ;

Gökbuget, N ;

Bartram, CR ;

Janssen, B ;

Rieder, H ;

Janssen, JWG ;

Fonatsch, C ;

Heyll, A ;

Voliotis, D ;

Beck, J ;

Lipp, T ;

Munzert, G ;

Maurer, J ;

Hoelzer, D ;

Thiel, E .

BLOOD, 2002, 99 (05) :1536-1543

[4] In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents [J].

Kano, Y ;

Akutsu, M ;

Tsunoda, S ;

Mano, H ;

Sato, Y ;

Honma, Y ;

Furukawa, Y .

BLOOD, 2001, 97 (07) :1999-2007

[5] A 5-DRUG REMISSION INDUCTION REGIMEN WITH INTENSIVE CONSOLIDATION FOR ADULTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA - CANCER AND LEUKEMIA GROUP-B STUDY-8811 [J].

LARSON, RA ;

DODGE, RK ;

BURNS, CP ;

LEE, EJ ;

STONE, RM ;

SCHULMAN, P ;

DUGGAN, D ;

DAVEY, FR ;

SOBOL, RE ;

FRANKEL, SR ;

HOOBERMAN, AL ;

WESTBROOK, CA ;

ARTHUR, DC ;

GEORGE, SL ;

BLOOMFIELD, CD ;

SCHIFFER, CA .

BLOOD, 1995, 85 (08) :2025-2037

[6] A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias [J].

Ottmann, OG ;

Druker, BJ ;

Sawyers, CL ;

Goldman, JM ;

Reiffers, J ;

Silver, RT ;

Tura, S ;

Fischer, T ;

Deininger, MW ;

Schiffer, CA ;

Baccarani, M ;

Gratwohl, A ;

Hochhaus, A ;

Hoelzer, D ;

Fernandes-Reese, S ;

Gathmann, I ;

Capdeville, R ;

O'Brien, SG .

BLOOD, 2002, 100 (06) :1965-1971

[7] In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells [J].

Scappini, B ;

Onida, F ;

Kantarjian, HM ;

Dong, L ;

Verstovsek, S ;

Keating, MJ ;

Beran, M .

CANCER, 2002, 94 (10) :2653-2662

[8] Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells [J].

Thiesing, JT ;

Ohno-Jones, S ;

Kolibaba, KS ;

Druker, BJ .

BLOOD, 2000, 96 (09) :3195-3199

[9] Synergistic activity of the new ABL-specific tyrosine kinase inhibitor ST1571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells [J].

Topaly, J ;

Zeller, WJ ;

Fruehauf, S .

LEUKEMIA, 2001, 15 (03) :342-347

[10]

Wetzler M, 1999, BLOOD, V93, P3983

← 1 →